JP2018504094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504094A5 JP2018504094A5 JP2017529750A JP2017529750A JP2018504094A5 JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5 JP 2017529750 A JP2017529750 A JP 2017529750A JP 2017529750 A JP2017529750 A JP 2017529750A JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- chain variable
- variable region
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 173
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 158
- 239000000427 antigen Substances 0.000 claims description 150
- 102000036639 antigens Human genes 0.000 claims description 150
- 108091007433 antigens Proteins 0.000 claims description 150
- 230000004048 modification Effects 0.000 claims description 112
- 238000012986 modification Methods 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 230000028993 immune response Effects 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 22
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 16
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 201000000564 macroglobulinemia Diseases 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000036039 immunity Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029515A JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088164P | 2014-12-05 | 2014-12-05 | |
| US62/088,164 | 2014-12-05 | ||
| PCT/US2015/064134 WO2016090337A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Division JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504094A JP2018504094A (ja) | 2018-02-15 |
| JP2018504094A5 true JP2018504094A5 (enExample) | 2019-01-17 |
| JP7174522B2 JP7174522B2 (ja) | 2022-11-17 |
Family
ID=56092578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529750A Active JP7174522B2 (ja) | 2014-12-05 | 2015-12-04 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Pending JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Pending JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11059891B2 (enExample) |
| EP (2) | EP3227436B1 (enExample) |
| JP (3) | JP7174522B2 (enExample) |
| KR (1) | KR20170108946A (enExample) |
| CN (2) | CN116063565A (enExample) |
| AU (2) | AU2015357543B2 (enExample) |
| BR (1) | BR112017011936A8 (enExample) |
| CA (1) | CA2974434A1 (enExample) |
| IL (2) | IL252655B (enExample) |
| MX (1) | MX395028B (enExample) |
| MY (1) | MY192062A (enExample) |
| NZ (1) | NZ732570A (enExample) |
| PH (1) | PH12017501041A1 (enExample) |
| SG (2) | SG11201704550XA (enExample) |
| WO (1) | WO2016090337A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX395028B (es) | 2014-12-05 | 2025-03-24 | Memorial Sloan Kettering Cancer Center | Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos. |
| HK1254803A1 (zh) * | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| JP7267009B2 (ja) | 2015-12-04 | 2023-05-01 | メモリアル スローン ケタリング キャンサー センター | Ｆｃ受容体様５を標的とする抗体および使用方法 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| US12065498B2 (en) | 2017-09-29 | 2024-08-20 | Cell Design Labs, Inc. | Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same |
| WO2019084538A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF |
| TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| SG11202003893UA (en) | 2017-12-29 | 2020-05-28 | Ap Biosciences Inc | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| EP3737692A4 (en) * | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| RU2756899C1 (ru) * | 2018-02-28 | 2021-10-06 | ЭйПи БАЙОСАЙЕНСИЗ, ИНК. | Бифункциональные белки, комбинирующие блокаду контрольной точки, для таргетной терапии |
| WO2019210155A1 (en) * | 2018-04-26 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for retrieving tumor-related antibodies and antigens |
| AU2019269118B2 (en) | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| TWI848951B (zh) | 2018-06-01 | 2024-07-21 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP3856775B9 (en) | 2018-09-27 | 2025-01-22 | Autolus Limited | Chimeric antigen receptor |
| WO2020086328A1 (en) * | 2018-10-25 | 2020-04-30 | The Medical College Of Wisconsin, Inc. | Targeting clptm1l for treatment and prevention of cancer |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| US11142586B2 (en) | 2019-08-07 | 2021-10-12 | Aqualung Therapeutics | Anti-human nicotinamide phosphoribosyltransferase (NAMPT) antibodies |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021242961A1 (en) * | 2020-05-27 | 2021-12-02 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| CN113801228B (zh) * | 2020-06-17 | 2023-01-17 | 常州费洛斯药业科技有限公司 | 靶向cd38的单链抗体、全人源嵌合抗原受体、制备方法和应用 |
| KR20230090367A (ko) | 2020-11-04 | 2023-06-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| JP2024523316A (ja) * | 2021-06-18 | 2024-06-28 | オートラス リミテッド | Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用 |
| KR20240040783A (ko) * | 2021-07-29 | 2024-03-28 | 소노마 바이오테라퓨틱스, 인크. | 자가면역 질환을 치료하기 위한 조절 t 세포를 표적화하는 윤활 세포외 기질-특이적 키메라 항원 수용체 |
| WO2023200873A2 (en) * | 2022-04-12 | 2023-10-19 | Washington University | Chimeric antigen receptor compositions and methods of using the same |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| AU2023272490A1 (en) | 2022-05-17 | 2024-12-12 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| KR20250022800A (ko) | 2022-06-10 | 2025-02-17 | 우모자 바이오파마 인코포레이티드 | 조작된 줄기 세포 및 그의 용도 |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024036096A2 (en) * | 2022-08-08 | 2024-02-15 | Eli Lilly And Company | Transferrin receptor binding proteins and conjugates |
| JP2025531850A (ja) | 2022-09-08 | 2025-09-25 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ |
| TW202434735A (zh) | 2022-11-04 | 2024-09-01 | 美商烏莫賈生物製藥股份有限公司 | 展示黏著分子融合的顆粒 |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| SK281964B6 (sk) | 1993-09-03 | 2001-09-11 | Chugai Seiyaku Kabushiki Kaisha | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm |
| EP1232392B2 (de) | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| KR20070115881A (ko) * | 2005-01-12 | 2007-12-06 | 메다렉스, 인코포레이티드 | 아이아르티에이-2 항체 및 그의 용도 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20210108497A (ko) * | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| SG10201900931XA (en) * | 2014-12-05 | 2019-02-27 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| MX395028B (es) | 2014-12-05 | 2025-03-24 | Memorial Sloan Kettering Cancer Center | Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos. |
| JP7267009B2 (ja) * | 2015-12-04 | 2023-05-01 | メモリアル スローン ケタリング キャンサー センター | Ｆｃ受容体様５を標的とする抗体および使用方法 |
-
2015
- 2015-12-04 MX MX2017007249A patent/MX395028B/es unknown
- 2015-12-04 EP EP15864773.5A patent/EP3227436B1/en active Active
- 2015-12-04 NZ NZ732570A patent/NZ732570A/en not_active IP Right Cessation
- 2015-12-04 CN CN202211233565.5A patent/CN116063565A/zh active Pending
- 2015-12-04 CA CA2974434A patent/CA2974434A1/en active Pending
- 2015-12-04 JP JP2017529750A patent/JP7174522B2/ja active Active
- 2015-12-04 SG SG11201704550XA patent/SG11201704550XA/en unknown
- 2015-12-04 AU AU2015357543A patent/AU2015357543B2/en active Active
- 2015-12-04 MY MYPI2017000852A patent/MY192062A/en unknown
- 2015-12-04 SG SG10202008076RA patent/SG10202008076RA/en unknown
- 2015-12-04 EP EP24206281.8A patent/EP4506036A3/en active Pending
- 2015-12-04 WO PCT/US2015/064134 patent/WO2016090337A1/en not_active Ceased
- 2015-12-04 CN CN201580075562.5A patent/CN109072199B/zh active Active
- 2015-12-04 BR BR112017011936A patent/BR112017011936A8/pt not_active IP Right Cessation
- 2015-12-04 KR KR1020177018388A patent/KR20170108946A/ko not_active Ceased
-
2017
- 2017-06-04 IL IL252655A patent/IL252655B/en unknown
- 2017-06-05 PH PH12017501041A patent/PH12017501041A1/en unknown
- 2017-06-05 US US15/614,108 patent/US11059891B2/en active Active
-
2021
- 2021-05-27 US US17/332,853 patent/US12139538B2/en active Active
- 2021-11-04 IL IL287835A patent/IL287835A/en unknown
-
2022
- 2022-01-20 AU AU2022200381A patent/AU2022200381A1/en not_active Abandoned
- 2022-02-28 JP JP2022029515A patent/JP2022066290A/ja not_active Withdrawn
-
2024
- 2024-02-13 JP JP2024019513A patent/JP2024040376A/ja active Pending
- 2024-10-08 US US18/909,536 patent/US20250059283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504094A5 (enExample) | ||
| JP2017537925A5 (enExample) | ||
| JP2017537629A5 (enExample) | ||
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP7404335B2 (ja) | Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用 | |
| JP2022116230A (ja) | 免疫療法用改変細胞 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2022066290A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2015527070A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2016520074A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2019521645A5 (enExample) | ||
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| IL275391B2 (en) | Antibodies binding ctla-4 and uses thereof | |
| CN113603788A (zh) | 免疫调节剂 | |
| IT201800003464A1 (it) | Cellule T CAR-CD30 per il trattamento di tumori CD30+ | |
| JP2020512973A5 (enExample) | ||
| JP2018500337A5 (enExample) | ||
| Qian et al. | The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing | |
| CN111971059A (zh) | 使用过继细胞疗法和检查点抑制剂的组合疗法 | |
| WO2022147222A1 (en) | Antibodies to tnfr2 and uses thereof |